Friday, April 23, 2021

Latest Posts

Orthocell: Receives new U.S. patent for CelGro

  • Regenerative medicine company Orthocell (OCC) has granted a new U.S. divisional patent for CelGro
  • The healthcare stock also focusses on regenerating mobility in patients by developing products for the repair of soft tissue injuries.
  • CelGro, a customisable collagen medical device manufactured by the company at its facility in WA using the company‚Äôs SMRT tissue engineering process
  • The new U.S. divisional patents expire in June 2033 and provide additional intellectual property to protect the CelGro platform
  • CelGro dental, recently renamed Striate+, the first product from the CelGro platform technology to gain U.S., European and Australian approval
  • Orthocell is down 1.79 per cent, trading at 55 cents

 

Latest Posts

Don't Miss